Madison, New Jersey headquartered Quest Diagnostics Inc.'s stock finished Wednesday's session 0.60% lower at $92.04 with a total trading volume of 890,320 shares. The Company's shares have advanced 5.44% in the past month, 7.88% over the previous three months, and 32.10% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.52% and 14.59%, respectively. Furthermore, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have a Relative Strength Index (RSI) of 66.77.
On December 12th, 2016, research firm Goldman upgraded the Company's stock rating from 'Neutral' to 'Buy'.
On December 15th, 2016, Quest Diagnostics announced that its Board of Directors elected Stephen H. Rusckowski, the Company's President and Chief Executive Officer, to serve in the additional position of Chairman of the Board of Directors. The Company's independent directors also designated Dr. Daniel C. Stanzione, Ph.D. as Lead Independent Director. Both appointments are effective January 01st, 2017. The free research report on DGX is available at:
Shares in San Diego, California headquartered DexCom Inc. ended at $63.74, up 0.28% from the last trading session. The stock recorded a trading volume of 2.04 million shares, which was above its three months average volume of 1.30 million shares. The Company's shares are trading 9.76% below their 50-day moving average. Moreover, shares of DexCom, which focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 36.60.
On December 19th, 2016, research firm Oppenheimer upgraded the Company's stock rating from 'Perform' to 'Outperform'.
On December 20th, 2016, Dexcom announced that the US Food and Drug Administration (FDA) has approved its G5 Mobile CGM system as the first and only continuous glucose monitoring system that can be used to make daily diabetes treatment decisions without finger pricking. The new "non-adjunctive" indication expands use of the Dexcom G5 Mobile CGM system as a replacement to finger stick glucose testing for diabetes treatment decisions, positioning the device as the new standard of care in glucose monitoring for diabetes management. The complimentary report on DXCM can be downloaded at:
San Diego, California headquartered Organovo Holdings Inc.'s stock ended yesterday's session 3.26% lower at $3.56 with a total trading volume of 865,884 shares. The Company's shares have advanced 11.60% in the past month and 42.97% on an YTD basis. The stock is trading 11.09% above its 50-day moving average and 8.16% above its 200-day moving average. Additionally, shares of Organovo Holdings, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have an RSI of 56.69.
On December 14th, 2016, Organovo Holdings announced an exclusive distributor agreement with Cosmo Bio Co., Ltd. for its NovoViewTM Preclinical Services in Japan. CosmoBio is one of Japan's largest suppliers in the life science industry, and Organovo will work with CosmoBio's Drug Discovery Services team to gain direct access to customers and support projects throughout the Japanese biopharmaceutical industry. Visit us today and download our complete research report on ONVO for free at:
At the close on Wednesday, shares in Waltham, Massachusetts headquartered Alere Inc. recorded a trading volume of 839,842 shares, which was higher than their three months average volume of 668,710 shares. The stock finished 2.10% higher at $40.31. The Company's shares have gained 2.39% in the last one month and 3.12% since the start of this year. The stock is trading above its 50-day moving average by 0.56%. Furthermore, shares of Alere, which provides professional diagnostic products and services for infectious and cardiometabolic disease, and toxicology in the US, Europe, and internationally, have an RSI of 55.74.
On December 16th, 2016, Alere declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock. The dividend is payable on January 16th, 2017 to holders of record of Series B stock at the close of business on January 02nd, 2017. The Company stated that the payment will cover the amount of all dividends accrued from October 01st, 2016, through December 31st, 2016. Get free access to your technical report on ALR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA